Member Info for Bebeto

Every piece of news needs to be bigger now, as the MCAP rises so must be the drivers that pushes it higher. Going to be very interesting here there's all to play for.

Knocking on the door again LOL, there's resistance at every penny and half penny on the way up as it meets people's criteria to sell. The more times it knocks the more likely to push through to the next level.

Results are the carrot for the buyers. The bottom line is if there's more buyers buying than sellers selling the shareprice will rise.!

"Together with our advisors " it's being orchestrated all the way.
It's a simple buy & hold strategy here.!

Yes it's going to get quite interesting, the seller(s) has taken down the shareprice but they now need buyers to sell into, if they take the shareprice down too far they'll be crowded out by buyers. Anything under 3p has over 300%+ upside by general consensus.

I think the RNS was great and it all adds to getting SNG001 fast tracked. The trial data so far has been of the highest quality but it's on the small side, we needed to deliver as much data as possible to make up the numbers.! I think it's mission accomplished to get to where we are now. I'm not bothered about the short term shareprice as the next phase of news is going to take the shareprice up to the next level. The 5% brigade can do there thing and I'm just going to ride this all the way for maximum returns.

I don't hold many shares.. but when I do.. I hold them all the way.

https://www.malcysblog.com/2020/09/oil-price-premier-oil-united-oil-gas-and-finally/

Levi , another of my investments is in GSK FTSE 100 company and a lot their shareholders are also -30% down, it's all over the whole financial system.

The difference here is UOG has gone from a Exploration company to an Exploration & Production Company, therefore we are now generating revenues and profits compared to zero revenues and a loss of around £2M in years before. The bang for your buck has now multiplied because of this.

Looking at the RKH share transactions, the entire 18.3% position was cut up into 19 portions with the majority going into Institutional Investor funds, there maybe some shares get flipped but the majority definitely won't.! Also we know their floor which is 2.66p.

The seller(s) here, can bring the shareprice down as far as they want but they will have to join an ever increasing queue to buy back in which will give them a lesser effect on the shareprice as many more investors can see how massively undervalued the company really is and the balance sheet will prove this.

The CEO isn't the one bringing the shareprice down far from it in fact.

I've already said what's happening and the seller(s) are going to paint themselves into a corner because the company's balance sheet will dictate the shareprice sooner or later.

Sooner Institutional's take over the free float the better.! The 5% brigade will be left behind in the process.

My first buy in was at 0.62p which was straight after a 500% rise, there was a chap reckoned he'd made £80k Profits then.! Wonder if he's still holding LOL.?

Massive news coming.! Institutional's will cover placing & Big Pharma partner.! Most likely takeover IMO

Levi, of course not I was talking about myself.!

Duster, it comes with the territory impossible for every move to good but the company has already transformed into a profit making comp.

Hi, yes I got a reply this morning from the man himself. I had asked a technical question regarding the RKH shares.

Firstly to get a reply within 24hrs from a CEO, is a massive positive. To actually take the time to explain to a genuine private investor is fantastic.

Basically- The Institutional had allocated their shares between different internal funds which individually are below the 3% threshold for TR-1.

That makes perfect sense and therefore highly unlikely most will be flipped anytime soon.

I'm a long term holder here and will be for a long time to come. I really believe Brian & the BoD can grow this acorn into a Mid-Cap oak tree.

GLA.

The positive results fulfilled it's remit for the interim analysis , which was to support SNG001 in being fast tracked for treatment against Covid-19.

Synairgen announces positive data from interim analysis of SNG001 trial in COPD patients



- SNG001 well tolerated in this older population with a significant co-morbidity (COPD)

- Strong interferon driven antiviral biomarker response

- Data support future progression of SNG001 for exacerbating COPD patients

- Positive data supportive of SNG001 COVID-19 programme

They've held that News back IMO Emergency Approval Very Close.!

COPD treatment is worth £Billions alone.. well done Synairgen.

The shareprice keeps knocking on the door, lots of profit taking on the penny & half penny areas.

I've emailed the company for clarification regarding RKH shares, hopefully they will respond.

I wouldn't say that about Broker Notes, another share I'm invested in GGP has been in line with half a dozen of them so far.!